M87.171

✓ Billable

Osteonecrosis due to drugs, right ankle

Diseases of the musculoskeletal system and connective tissue (M00-M99)

Check This Code

❌ Excludes1

inherited

Rules inherited from parent codes in the hierarchy.

  • juvenile osteonecrosis (M91-M92)
  • osteochondropathies (M90-M93)

📋 Code Instructions

inherited
  • code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
  • code to identify major osseous defect, if applicable (M89.7-)

Clinical Description

ICD-10-CM code M87.171 represents osteonecrosis due to drugs, right ankle. This code falls under the Diseases of the musculoskeletal system and connective tissue (M00-M99) classification. It is a billable/specific code valid for HIPAA-covered transactions as of October 1, 2025 (FY2026). This code can be used to indicate a diagnosis for reimbursement purposes on insurance claims.

This is a 7-character code at the 6th level of specificity. This is the most specific code available in this subcategory. Coders should note that M87.171 has 2 Excludes1 restriction(s) — codes that cannot be reported together on the same claim.

Frequently Asked Questions

What is ICD-10 code M87.171?

ICD-10-CM code M87.171 is "Osteonecrosis due to drugs, right ankle". It belongs to the category: Diseases of the musculoskeletal system and connective tissue (M00-M99).

Is M87.171 a billable ICD-10 code?

Yes, M87.171 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.

What codes are excluded with M87.171?

M87.171 has 2 Excludes1 rule(s). These codes are mutually exclusive and cannot be coded together on the same claim.

🧪 Validate Combinations

Add M87.171 to the Excludes Checker to validate against your full code list.

Open in Checker →

Code Information

CodeM87.171
BillableYes
ParentM87.17
CategoryDiseases of the musculoskeletal system and connective tissue (M00-M99)
Excludes12 rule(s)
Excludes20 note(s)

Data Source

CMS ICD-10-CM 2026 Tabular List

Updated October 1, 2025 (FY2026)